Checkpoint immunotherapy is associated with preferential activation of tumor antigen–specific CD4+ T cells in MDS

Checkpoint immunotherapy is associated with preferential activation of tumor antigen–specific CD4+ T cells in MDS

Abstract: A growing body of literature suggests that the efficacy of DNA hypomethylating agents are mediated via activation of antitumor immune mechanisms. Based upon this hypothesis, early phase trials combining immune checkpoint inhibitors (ICIs) with azacitidine in patients with myelodysplastic s...

Full description

Saved in:
Bibliographic Details
Main Authors: Elizabeth A. Griffiths, Pragya Srivastava, Eduardo Cortes Gomez, Junko Matsuzaki, Kunle Odunsi, Laura W. Dillon, Devdeep Mukherjee, Christopher S. Hourigan, Jacqueline Peng, Shovik Bandyopadhyay, Kai Tan, Kristopher M. Attwood, Joseph B. Kuechle, Prashant K. Singh, Jianmin Wang, Michael J. Nemeth
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Blood Neoplasia
Online Access:http://www.sciencedirect.com/science/article/pii/S295032802500041X
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items